Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Completed · Phase 3

Conditions studied: Lymphoblastic Leukemia, Acute

In brief

The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.

Key facts

Study ID

NCT00137111

Run by

St. Jude Children's Research Hospital

People needed

501

Starts

2000-07-08

Expected to finish

2014-04-01

Last updated by the study team

2020-09-11

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of non-B-cell ALL by immunophenotyping, as determined by the reactivity pattern to a panel of monoclonal antibodies with flow cytometry as well as morphology and cytochemical staining.
• Age range: 1 to 18 years (inclusive).

You may not qualify if…

• Previously treated with chemotherapy for one week or longer.

Where it is running

• St Jude Children's Research Hospital — Memphis, Tennessee, United States
• Cook Children's Medical Center — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.